Rockefeller Capital Management
GPCR icon

Rockefeller Capital Management’s Structure Therapeutics GPCR Stock Holding History

Rockefeller Capital Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$135K Buy
2,514
+294
+13% +$13K ﹤0.01% 2817
2026
Q1 		$107K Buy
2,220
+1,489
+204% +$102K ﹤0.01% 2839
2025
Q4 		$50.8K Sell
731
-11
-1% -$449 ﹤0.01% 3058
2025
Q3 		$20.8K Buy
+742
New +$14.8K ﹤0.01% 3336

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Rockefeller Capital Management's GPCR Position: Q2 2026 in Review

Rockefeller Capital Management increased its Structure Therapeutics (GPCR) stake by 13% in Q2 2026, buying an estimated $13K and bringing the position to 2,514 shares worth $135K. The position accounts for ﹤0.01% of the portfolio, ranked #2817.

Rockefeller Capital Management first reported a position in GPCR in Q3 2025 and has held it in 4 quarters since. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Rockefeller Capital Management held 2,514 shares of Structure Therapeutics worth $135K as of Q2 2026.
  • Rockefeller Capital Management bought 294 Structure Therapeutics shares in Q2 2026, an estimated $13K.
  • Structure Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #2817 holding.
  • Rockefeller Capital Management first reported a position in Structure Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.